Regulatory Novartis receives European Commission approval for Itvisma for spinal muscular atrophy PharmaTimesEC backs first gene replacement therapy for broad sma populationRare DiseaseRead full story pharminent July 2, 2026 (Last updated: July 3, 2026) PharmaTimes EC backs first gene replacement therapy for broad sma population Rare Disease Read full story Post navigation Previous: AZ forges ever-closer ties with China’s CSPC PharmaNext: Biogen Bets on Tau at AAIC: Diranersen Phase 2 CELIA Data Related Stories Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026 Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026 Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 pharminent August 26, 2026